Relevant experimental models
Does the experimental setting represent the biological variation the model is intended to explain?
EIC Pre-Accelerator program
PRECISION-ECS: predicting cannabinoid response in melanoma
Our first program applies the EndoVia platform to cannabinoids and the endocannabinoid system in melanoma.
Funded by the European Union
Funded by the European Union under Horizon Europe, grant agreement No 101310106.
Why cannabinoids and melanoma
Cannabinoids show strong and broad anticancer activity in preclinical research, yet clinical translation remains inconsistent. Responses vary widely between tumors, and the biology behind that variation is poorly understood. Melanoma combines high molecular diversity with an active endocannabinoid system, which makes it a strong first test for response prediction.
What the program does
- Tests cannabinoids and formulations across a panel of molecularly diverse melanoma models
- Measures functional response, signaling and molecular profiles
- Builds and calibrates predictive response models for each tumor model
- Tests model predictions in new experiments and on models not used to build them
- Defines biomarker hypotheses and responder groups for further development
Where the program stands
Foundations
Research, IP and functional data
Our work builds on academic research, an IP foundation and growing experimental response datasets.
In development
Models and experimental validation
We are integrating functional and molecular data to develop response models and investigate their performance in relevant experimental systems.
Next
Stronger evidence for translation
The next stage is to evaluate predictive performance and reproducibility, then establish what further evidence is needed before clinical use.
A prediction needs a meaningful test.
Measured response
How closely do predictions correspond to observed sensitivity and resistance?
Reproducibility
Can the findings be reproduced beyond the data used to develop the model?
Translational relevance
What additional evidence would be needed to support decisions in a clinical setting?
Funding
Horizon Europe, EIC Pre-Accelerator (HORIZON-WIDERA-2025-02-ACCESS-01). Grant agreement No 101310106. Granting authority: European Innovation Council and SMEs Executive Agency (EISMEA). Duration: 1 July 2026 to 30 June 2028 (24 months). Coordinator: EndoVia Therapeutics d.o.o.
View project 101310106 on CORDIS →PRECISION-ECS has received funding from the European Union’s Horizon Europe programme under grant agreement No 101310106.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.
Working on response heterogeneity, biomarkers or cannabinoid oncology? Let’s talk.
Tell us about your compound and the decision ahead. A short, non-confidential description is enough to start.
Discuss a project